233 related articles for article (PubMed ID: 26334227)
1. Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?
Sibbing D; Gross L; Aradi D
Thromb Haemost; 2016 Jan; 115(1):3-6. PubMed ID: 26334227
[TBL] [Abstract][Full Text] [Related]
2. The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation.
Czerwińska-Jelonkiewicz K; Witkowski A; Dąbrowski M; Piotrowski W; Hryniewiecki T; Stępińska J
Arch Cardiovasc Dis; 2018 Apr; 111(4):233-245. PubMed ID: 29126843
[TBL] [Abstract][Full Text] [Related]
3. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
5. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
Ferreiro JL; Ueno M; Tello-Montoliu A; Tomasello SD; Seecheran N; Desai B; Rollini F; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2013 Feb; 6(2):182-4. PubMed ID: 23428011
[No Abstract] [Full Text] [Related]
6. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial.
Bonten TN; Saris A; van Oostrom MJ; Snoep JD; Rosendaal FR; Zwaginga J; Eikenboom J; van der Meer PF; van der Bom JG
Thromb Haemost; 2014 Dec; 112(6):1209-18. PubMed ID: 25208590
[TBL] [Abstract][Full Text] [Related]
7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
8. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
9. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
10. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
11. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
[TBL] [Abstract][Full Text] [Related]
13. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
[TBL] [Abstract][Full Text] [Related]
14. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
15. The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence.
Leunissen TC; De Borst GJ; Janssen PW; ten Berg JM
J Cardiovasc Surg (Torino); 2015 Apr; 56(2):165-75. PubMed ID: 25600432
[TBL] [Abstract][Full Text] [Related]
16. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
18. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
[TBL] [Abstract][Full Text] [Related]
19. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
[TBL] [Abstract][Full Text] [Related]
20. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
Thomas MR; Storey RF
J Cardiovasc Transl Res; 2014 Feb; 7(1):19-28. PubMed ID: 24309957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
